For example, EGFR inhibitor lapatinib has been shown to inhibit EGFRvIII in vitro by preferentially binding the inactive conformation of the kinase but fails to achieve sufficient intratumor concentrations in GBM patients. Here, EGFR is linked to glioblastoma.